One of the secrets to successful stockpicking in the biotech sector is
adequately valuing and pricing the risk/reward profile of a company's
pipeline. Almost every biotech looks cheap if an investor just assumes
that everything will work as planned, but the reality is that only a
small percentage of pipeline prospects live up to their potential. In
the case of Incyte (NASDAQ: INCY )
, this company does have a solid product in Jakafi, but it seems as
though the Street is already factoring in a fair bit of success for the
company's early stage pipeline.
Follow this link to the full article:
Is Incyte Corporation Overvalued?
No comments:
Post a Comment